Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 18/20 | 0.59 |
| ▸ | AKT1 | P31749 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065003 | 0.81 | AKT2 (0.65) | AKT2AKT1CYP2C9RPS6KB1ROCK2 | |
| SCHEMBL1002812 | 0.75 | AKT2 (0.72) | AKT2AKT1GSK3BCYP2C9CYP2D6 | |
| SCHEMBL1002126 | 0.74 | AKT2 (1.00) | AKT2AKT1GSK3BCYP2C9CYP2D6 | |
| SCHEMBL29367023 | 0.74 | AKT2 (1.00) | AKT2AKT1GSK3BCYP2C9CYP2D6 | |
| SCHEMBL14386234 | 0.73 | AKT2 (0.62) | AKT2AKT1GSK3BCYP2C9CYP2D6 | |
| SCHEMBL13229909 | 0.73 | AKT1 (0.69) | AKT2AKT1 | |
| SCHEMBL13855893 | 0.73 | HTR2C (0.53) | AKT2AKT1GSK3BCYP2D6RPS6KB1 | |
| SCHEMBL2778811 | 0.72 | AKT2 (0.76) | AKT2AKT1GSK3BCYP2C9CYP2D6 | |
| SCHEMBL13855514 | 0.72 | RPS6KB1 (0.60) | RPS6KB1HTR2C | |
| Hydrochloric Acid SCHEMBL2796785 | 0.72 | AKT1 (0.68) | AKT2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, CDK1 | AKT2 43/4885AKT1 72/4885GSK3B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.